KUR 211

Drug Profile

KUR 211

Alternative Names: I-020201; KUR-211

Latest Information Update: 21 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kuros Biosurgery
  • Developer Baxalta; Kuros Biosurgery
  • Class Blood proteins; Growth factors; Peptides
  • Mechanism of Action Platelet derived growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic foot ulcer

Most Recent Events

  • 21 Aug 2015 No recent reports on development identified - Phase-II for Diabetic foot ulcer in Europe (Topical)
  • 01 Sep 2011 Baxter and Kuro complete enrolment in their phase IIb trial for Diabetic foot ulcer in Europe
  • 07 Jul 2009 Phase-II clinical trials in Diabetic foot ulcer in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top